HUE064521T2 - Tamoxifen alkalmazása cisztás fibrózis kezelésére nem nõi pácienseknél - Google Patents

Tamoxifen alkalmazása cisztás fibrózis kezelésére nem nõi pácienseknél

Info

Publication number
HUE064521T2
HUE064521T2 HUE17715154A HUE17715154A HUE064521T2 HU E064521 T2 HUE064521 T2 HU E064521T2 HU E17715154 A HUE17715154 A HU E17715154A HU E17715154 A HUE17715154 A HU E17715154A HU E064521 T2 HUE064521 T2 HU E064521T2
Authority
HU
Hungary
Prior art keywords
tamoxifen
treatment
cystic fibrosis
female patients
patients
Prior art date
Application number
HUE17715154A
Other languages
English (en)
Inventor
Giorgio Balduzzi
Original Assignee
Gb Pharma S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gb Pharma S R L filed Critical Gb Pharma S R L
Publication of HUE064521T2 publication Critical patent/HUE064521T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE17715154A 2016-04-05 2017-04-03 Tamoxifen alkalmazása cisztás fibrózis kezelésére nem nõi pácienseknél HUE064521T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A002292A ITUA20162292A1 (it) 2016-04-05 2016-04-05 Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi

Publications (1)

Publication Number Publication Date
HUE064521T2 true HUE064521T2 (hu) 2024-03-28

Family

ID=56551460

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17715154A HUE064521T2 (hu) 2016-04-05 2017-04-03 Tamoxifen alkalmazása cisztás fibrózis kezelésére nem nõi pácienseknél

Country Status (13)

Country Link
US (1) US11191738B2 (hu)
EP (1) EP3439645B1 (hu)
JP (1) JP2019510791A (hu)
CN (1) CN109310652A (hu)
CA (1) CA3018024A1 (hu)
EA (1) EA036682B1 (hu)
ES (1) ES2951263T3 (hu)
HR (1) HRP20231197T1 (hu)
HU (1) HUE064521T2 (hu)
IT (1) ITUA20162292A1 (hu)
PL (1) PL3439645T3 (hu)
RS (1) RS64640B1 (hu)
WO (1) WO2017174529A1 (hu)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174388T3 (es) * 1997-06-27 2002-11-01 Akzo Nobel Nv Solucion liquida de medicamento para administracion oral.
WO2009105234A2 (en) * 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
WO2012134965A1 (en) 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases

Also Published As

Publication number Publication date
HRP20231197T1 (hr) 2024-01-19
EA201891911A1 (ru) 2019-04-30
CA3018024A1 (en) 2017-10-12
EA036682B1 (ru) 2020-12-08
RS64640B1 (sr) 2023-10-31
EP3439645B1 (en) 2023-07-05
EP3439645C0 (en) 2023-07-05
ES2951263T3 (es) 2023-10-19
ITUA20162292A1 (it) 2017-10-05
PL3439645T3 (pl) 2023-08-21
WO2017174529A1 (en) 2017-10-12
JP2019510791A (ja) 2019-04-18
CN109310652A (zh) 2019-02-05
US11191738B2 (en) 2021-12-07
US20200297667A1 (en) 2020-09-24
EP3439645A1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
HK1258396A1 (zh) 用於治療纖維化的賽尼克韋羅聯合療法
IL250960B (en) Combined treatment of sinecriviroc for the treatment of leprosy
EP3204007C0 (en) TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
IL247969B (en) A medicinal component for use in the treatment of infections
ZA201906473B (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
IL246855A0 (en) Materials for use in the treatment of retinitis
HUE050456T2 (hu) Dimetil-amino-mikeliolid tüdõfibrózis kezelésében történõ alkalmazásra
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
IL247882B (en) The composition for use in the treatment of pain associated with an intervertebral disc
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
IL257930A (en) A composition for use in the treatment of intervertebral disc-related pain
RS64640B1 (sr) Upotreba tamoksifena za lečenje cistične fibroze kod pacijenata koji nisu žene
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido